The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research Report: Human UBA7 / UBE1L (UniProt P41226) — Functional Annotation and Current Understanding

1) Target identity verification (critical)

The literature retrieved and analyzed corresponds to the human gene UBA7 (synonyms UBE1L, “ubiquitin-like modifier-activating enzyme 7”), which functions as the E1 activating enzyme in the ISG15 conjugation (ISGylation) pathway. This matches the UniProt accession P41226 description (E1-family enzyme with E1-like domains) and is consistently used in recent structural and functional studies. (afsar2023cryoemstructuresof pages 1-2, wallace2023insightsintothe pages 1-2, madaan2024isgylationenhancesdsrnainduced pages 1-2)

2) Key concepts and definitions (current consensus)

2.1 ISG15 and ISGylation

ISG15 is an interferon-stimulated ubiquitin-like (UBL) protein produced as a precursor that is proteolytically matured to expose a C-terminal glycine motif required for conjugation (often described as LR(L/R)GG, depending on review). (sarkar2023isg15itsroles pages 1-2, alvarez2024unveilingthemultifaceted pages 2-4)

ISGylation is defined as a reversible post-translational modification in which ISG15 is covalently conjugated to lysine residues on substrate proteins via an E1–E2–E3 enzyme cascade analogous to ubiquitination but largely distinct in biological outcomes. (sarkar2023isg15itsroles pages 1-2, bonacci2025digdubsmechanismsand pages 2-3, alvarez2024unveilingthemultifaceted pages 2-4)

2.2 Where UBA7 fits

UBA7/UBE1L is the E1 enzyme that performs the first step in the ISGylation cascade: it activates ISG15 for transfer to the E2 enzyme. A recent primary study explicitly states that UBA7/UBE1L encodes the only ISG15-activating enzyme identified to date. (madaan2024isgylationenhancesdsrnainduced pages 1-2)

3) Biochemical function: reaction catalyzed and substrate specificity

3.1 Reaction catalyzed (E1 chemistry)

Recent high-resolution structural and biochemical work supports that human UBA7 follows the canonical E1 mechanism for UBL activation:

1. ATP-dependent adenylation of the ISG15 C-terminus (forming an ISG15 adenylate intermediate).
2. Formation of an E1~ISG15 thioester at the UBA7 catalytic cysteine.
3. Transthiolation (E1→E2 transfer) to the catalytic cysteine of the cognate E2, UBE2L6 (UbcH8), generating UBE2L6~ISG15, which then supports E3-mediated isopeptide bond formation on substrates. (afsar2023cryoemstructuresof pages 1-2, wallace2023insightsintothe pages 1-2, wallace2023insightsintothe pages 10-11)

Wallace et al. (Nature Communications; published 2023-12; https://doi.org/10.1038/s41467-023-43711-3) report in vitro charging and transfer assays with explicit time courses (0–900 s) and representative concentrations/conditions (e.g., E1 charging with 2.5 µM UBE1L and 3 µM ISG15; multi-turnover assays with 0.25 µM UBE1L, 2 µM UBE2L6, 5 µM ISG15, 25 °C), anchoring these mechanistic steps experimentally. (wallace2023insightsintothe pages 10-11, wallace2023insightsintothe pages 6-7)

3.2 Substrate specificity (ISG15 versus ubiquitin)

UBA7 is widely treated as an ISG15-dedicated E1, contrasted with the ubiquitin E1 UBA1 in parallel biochemical contexts. (clancy2023isgylationindependentprotectionof pages 1-2, wallace2023insightsintothe pages 10-11)

Mechanistic specificity determinants were clarified by 2023 cryo-EM structural studies:

• ISG15’s C-terminal UBL domain (“C-lobe”) makes an extensive interaction network with UBA7’s adenylation region, whereas the ISG15 N-lobe is dispensable for forming E1 and E2 thioesters (i.e., activation and E1→E2 transfer can proceed without the N-lobe contribution). (wallace2023insightsintothe pages 6-7)
• An ISG15 Thr125 patch functions as a negative selector against mis-activation by the ubiquitin E1 UBA1, contributing to pathway fidelity (ISG15 charging by the “wrong” E1). (wallace2023insightsintothe pages 6-7)
• Wallace et al. further demonstrated that engineered ISG15 and UBE2L6 mutants can shift selectivity between ISG15 and ubiquitin conjugation pathways, implying specificity is encoded by defined interface determinants rather than generic E1 chemistry. (wallace2023insightsintothe pages 1-2, wallace2023insightsintothe pages 6-7)

Two complementary 2023 Nature Communications papers provided structural snapshots of UBA7/UBE1L complexes with ISG15 intermediates and UBE2L6 that together explain how specificity is achieved for both the modifier (ISG15) and the cognate E2 (UBE2L6). (afsar2023cryoemstructuresof pages 1-2, wallace2023insightsintothe pages 1-2)

4) Pathway partners, biological processes, and (inferred) localization

4.1 Core E2 and E3 partners

E2 partner (required for downstream conjugation):
* UBE2L6 / UbcH8 is the canonical cognate E2 for ISG15 transfer from UBA7. (afsar2023cryoemstructuresof pages 1-2, wallace2023insightsintothe pages 1-2, sarkar2023isg15itsroles pages 1-2)

E3 ligases (examples with strong support in recent reviews and experiments):
* HERC5 is emphasized as the dominant human ISG15 E3 ligase in reviews (loss of HERC5 markedly reduces observable ISGylation), and it is central in viral restriction examples. (bonacci2025digdubsmechanismsand pages 3-3, alvarez2024unveilingthemultifaceted pages 2-4)
* TRIM25/EFP and ARIH1 are also reported as ISG15 E3 ligases (with TRIM25/ARIH1 being dual-function enzymes in ubiquitin contexts). (sarkar2023isg15itsroles pages 1-2, alvarez2024unveilingthemultifaceted pages 2-4)

4.2 Regulation by interferon signaling

Type I interferons induce ISGylation pathway components through IFNAR1/IFNAR2 → JAK/STAT → ISGF3 nuclear transcriptional activation of interferon-stimulated genes. (bonacci2025digdubsmechanismsand pages 2-3)

A 2023 study highlights a key regulatory nuance: in some contexts, USP18 early expression after interferon can suppress UBA7 expression, limiting ISGylation despite interferon responsiveness (shown in HCT116 cells; USP18 depletion restored interferon-dependent expression of UBA7 and UBE2L6/UBCH8 and rescued ISGylation). (clancy2023isgylationindependentprotectionof pages 1-2, clancy2023isgylationindependentprotectionof pages 3-4)

4.3 Cellular localization: what is known and what remains uncertain

The retrieved 2023–2024 evidence clearly places UBA7 function in intracellular ISGylation cascades and in settings consistent with cytosolic innate immune signaling (e.g., ISGylation of viral proteins; modulation of cytosolic nucleic acid sensing). (sarkar2023isg15itsroles pages 1-2, zhu2024isgylationofthe pages 2-5, madaan2024isgylationenhancesdsrnainduced pages 5-6)

However, within the retrieved excerpts, direct experimental statements localizing UBA7 itself to a specific compartment (cytosol vs nucleus; organelle association) are limited. Some reviews describe HERC5-linked ISGylation as acting on newly synthesized proteins (consistent with ribosome-proximal/cytosolic activity), but this does not, by itself, prove UBA7’s steady-state subcellular distribution. This is a limitation of the current evidence set. (sarkar2023isg15itsroles pages 2-4, alvarez2024unveilingthemultifaceted pages 2-4)

5) Recent developments and latest research (prioritizing 2023–2024)

5.1 2023: Structural mechanism of UBA7 activation and E1→E2 transfer

Two 2023 Nature Communications papers are central advances:

• Afsar et al. (published 2023-08; https://doi.org/10.1038/s41467-023-39780-z) present cryo-EM structures of human UBA7 in complexes poised for catalysis with UBE2L6, ISG15 adenylate, and ISG15 thioester intermediates, illuminating why UBA7 is exquisitely specific for ISG15 and UBE2L6. (afsar2023cryoemstructuresof pages 1-2)
• Wallace et al. (published 2023-12; https://doi.org/10.1038/s41467-023-43711-3) provide a 3.45 Å cryo-EM structure of a trapped UBE1L(UBA7)–UBE2L6–activated ISG15 complex and biochemical mutational analyses that identify specificity determinants (e.g., C-lobe engagement; N-lobe dispensability for thioester formation; Thr125 patch influencing cross-pathway mis-activation). (wallace2023insightsintothe pages 1-2, wallace2023insightsintothe pages 6-7)

5.2 2024: UBA7/ISGylation in innate immune signaling and epithelial immunity

• Madaan et al. (Journal of Biological Chemistry; published 2024-09; https://doi.org/10.1016/j.jbc.2024.107686) used human epithelial cells with UBA7-null clones and found that loss of ISGylation (UBA7-null) reduced Poly I:C-triggered NF-κB activation (p-RELA ≈30% of parental in one summary) and reduced Poly I:C-induced IFNB1 transcript induction to ≈50% of parental, with statistics summarized across 3–6 experiments (star-thresholds reported in the paper). (madaan2024isgylationenhancesdsrnainduced pages 5-6, madaan2024isgylationenhancesdsrnainduced pages 4-5)
• Zhu et al. (Journal of Virology; published 2024-09; https://doi.org/10.1128/jvi.00869-24) show that the ISGylation machinery (E1 UBA7, E2 UBE2L6, E3 HERC5) targets SARS-CoV-2 nucleocapsid (N). They map four major ISGylation sites (K266, K355, K387, K388), show that endogenous ISGylation can be induced by IFN-α (1,000 U/mL, 24 h), and demonstrate that ISGylation impairs N oligomerization and suppresses viral RNA synthesis in a replicon system; importantly, the ISGylated fraction is <5% yet can exert a dominant-negative effect on N assembly. (zhu2024isgylationofthe pages 2-5, zhu2024isgylationofthe pages 11-13, zhu2024isgylationofthe pages 5-7)

6) Current applications and real-world implementations

6.1 Antiviral restriction mechanisms and viral antagonism

UBA7’s most immediate “real-world” biological role is in interferon-driven antiviral defense, by enabling ISGylation of host and viral proteins.

In SARS-CoV-2, a clear implementation-level mechanism is that HERC5-mediated ISGylation of N disrupts N oligomerization/assembly and inhibits viral RNA synthesis, while the viral PLpro/NSP3 counters by deISGylation; pharmacological PLpro inhibition increases detectable N ISGylation during infection. (zhu2024isgylationofthe pages 2-5, zhu2024isgylationofthe pages 11-13)

6.2 Innate immune pathway modulation (cGAS-STING)

A 2024 preprint reports that deficiency of ISG15 or UBA7 attenuates cGAS-STING downstream gene expression and antiviral ability in mouse and human cells, and that UBA7 knockdown facilitated HSV-1 infection; the same study mapped multiple cGAS ISGylation lysines (K21, K187, K219, K458). While preprints warrant caution versus peer-reviewed final versions, this provides a mechanistic, testable model linking UBA7-dependent ISGylation to cytosolic DNA sensing. (chu2024herc5catalyzedisgylationpotentiates pages 1-4)

6.3 Therapeutic/frontier framing from expert reviews

A 2024 expert review argues that ISG15 has “therapeutic frontier” potential spanning immunomodulation, vaccine contexts, and cancer biology, and explicitly places UBA7 (human) / Ube1L (mouse) as the upstream E1 enzyme in that pathway. (alvarez2024unveilingthemultifaceted pages 2-4)

7) Disease relevance, expert opinion, and translational signals

7.1 Cancer context (ISG15/ISGylation axis)

Reviews emphasize that ISG15/ISGylation can have context-dependent pro- or anti-tumor roles, motivating interest in pathway components including UBA7 as biomarkers or modulators; UBA7 is typically presented as the E1 required for intracellular ISGylation. (alvarez2024unveilingthemultifaceted pages 2-4, yuan2023thefunctionalroles pages 2-5, yuan2023thefunctionalroles pages 1-2)

7.2 Genetics / association-level evidence (Open Targets)

Open Targets reports association evidence between UBA7 and multiple conditions (e.g., dengue disease, breast cancer, heart failure) with modest aggregate scores (example: dengue disease association score ~0.37; breast cancer ~0.24 in the displayed results), reflecting heterogeneous evidence types rather than direct mechanistic causality. These associations are best treated as hypothesis-generating until supported by direct functional genetics. (OpenTargets Search: -UBA7)

7.3 Clinical trials

A broad ClinicalTrials.gov-style search returned trials in the system, but none clearly represent direct UBA7-targeting interventions (e.g., no UBA7 inhibitors in trials were identified by the query). This aligns with the notion that pathway manipulation is currently more feasible through upstream interferon signaling, viral protease antagonism (e.g., PLpro), or downstream effectors rather than direct UBA7 targeting. (clancy2023isgylationindependentprotectionof pages 1-2)

8) Key statistics and data points from recent studies (examples)

• Cryo-EM structure resolution of UBE1L(UBA7)–UBE2L6–ISG15 complex: 3.45 Å (Wallace et al., 2023-12). (wallace2023insightsintothe pages 1-2)
• Charging/transfer assay timepoints reported: 0, 15, 30, 60, 300, 900 seconds (Wallace et al., 2023-12). (wallace2023insightsintothe pages 6-7)
• SARS-CoV-2 N ISGylation fraction <5% yet dominant-negative on oligomerization/assembly (Zhu et al., 2024-09). (zhu2024isgylationofthe pages 11-13)
• SARS-CoV-2 N ISGylation sites: K266, K355, K387, K388 (Zhu et al., 2024-09). (zhu2024isgylationofthe pages 5-7)
• In UBA7-null epithelial cells, Poly I:C-triggered NF-κB activation p-RELA ≈30% of parental and Poly I:C-induced IFNB1 induction ≈50% of parental (Madaan et al., 2024-09; statistical significance thresholds reported). (madaan2024isgylationenhancesdsrnainduced pages 5-6)

9) Visual evidence: pathway and structure

Wallace et al. provide (i) a schematic of the ISG15 activation/transfer cascade via UBE1L(UBA7)→UBE2L6 and (ii) cryo-EM structural depiction of the complex, useful for interpreting domain organization and the relay mechanism. (wallace2023insightsintothe media bf4518e2, wallace2023insightsintothe media afc40555)

10) Summary: functional annotation statement (human UBA7)

Human UBA7/UBE1L (UniProt P41226) is the E1 enzyme dedicated to ISG15 activation, catalyzing ATP-dependent ISG15 adenylation and formation of an E1~ISG15 thioester, followed by transfer to the E2 UBE2L6 to drive E3-dependent ISGylation (notably via HERC5, and also TRIM25/EFP and ARIH1 in some contexts). Its activity is embedded in type I/III interferon signaling and under negative regulation in some cellular contexts by USP18-linked feedback, enabling dynamic control of ISGylation magnitude during innate immune responses. Recent (2023) cryo-EM structures reveal molecular determinants ensuring specificity for ISG15 and UBE2L6, and 2024 studies connect UBA7-dependent ISGylation to dsRNA-triggered inflammatory signaling and direct restriction of SARS-CoV-2 replication by targeting viral nucleocapsid assembly. (afsar2023cryoemstructuresof pages 1-2, wallace2023insightsintothe pages 1-2, wallace2023insightsintothe pages 6-7, madaan2024isgylationenhancesdsrnainduced pages 5-6, zhu2024isgylationofthe pages 11-13)

Evidence map (artifact)

Table: This table summarizes verified functional annotation for human UBA7/UBE1L (UniProt P41226), including enzymatic mechanism, ISG15 specificity, pathway partners, regulation, and recent high-value studies. It is useful as a compact evidence map linking structural, biochemical, and cell-based findings to the ISGylation pathway.

References

1. (afsar2023cryoemstructuresof pages 1-2): Mohammad Afsar, GuanQun Liu, Lijia Jia, Eliza A. Ruben, Digant Nayak, Zuberwasim Sayyad, Priscila dos Santos Bury, Kristin E. Cano, Anindita Nayak, Xiang Ru Zhao, Ankita Shukla, Patrick Sung, Elizabeth V. Wasmuth, Michaela U. Gack, and Shaun K. Olsen. Cryo-em structures of uba7 reveal the molecular basis for isg15 activation and e1-e2 thioester transfer. Nature Communications, Aug 2023. URL: https://doi.org/10.1038/s41467-023-39780-z, doi:10.1038/s41467-023-39780-z. This article has 31 citations and is from a highest quality peer-reviewed journal.

2. (wallace2023insightsintothe pages 1-2): Iona Wallace, Kheewoong Baek, J. Rajan Prabu, Ronnald Vollrath, Susanne von Gronau, Brenda A. Schulman, and Kirby N. Swatek. Insights into the isg15 transfer cascade by the ube1l activating enzyme. Nature Communications, Dec 2023. URL: https://doi.org/10.1038/s41467-023-43711-3, doi:10.1038/s41467-023-43711-3. This article has 29 citations and is from a highest quality peer-reviewed journal.

3. (madaan2024isgylationenhancesdsrnainduced pages 1-2): Vidushi Madaan, Alexandra Kollara, David Spaner, and Theodore J. Brown. Isgylation enhances dsrna-induced interferon response and nfκb signaling in fallopian tube epithelial cells. Journal of Biological Chemistry, 300:107686, Sep 2024. URL: https://doi.org/10.1016/j.jbc.2024.107686, doi:10.1016/j.jbc.2024.107686. This article has 7 citations and is from a domain leading peer-reviewed journal.

4. (sarkar2023isg15itsroles pages 1-2): Lucky Sarkar, GuanQun Liu, and Michaela U. Gack. Isg15: its roles in sars-cov-2 and other viral infections. Trends in Microbiology, 31:1262-1275, Dec 2023. URL: https://doi.org/10.1016/j.tim.2023.07.006, doi:10.1016/j.tim.2023.07.006. This article has 55 citations and is from a domain leading peer-reviewed journal.

5. (alvarez2024unveilingthemultifaceted pages 2-4): Enrique Álvarez, Michela Falqui, Laura Sin, Joseph Patrick McGrail, Beatriz Perdiguero, Rocío Coloma, Laura Marcos-Villar, Céline Tárrega, Mariano Esteban, Carmen Elena Gómez, and Susana Guerra. Unveiling the multifaceted roles of isg15: from immunomodulation to therapeutic frontiers. Vaccines, 12:153, Feb 2024. URL: https://doi.org/10.3390/vaccines12020153, doi:10.3390/vaccines12020153. This article has 42 citations.

6. (bonacci2025digdubsmechanismsand pages 2-3): Thomas Bonacci and Michael J. Emanuele. Dig-dubs: mechanisms and functions of isg15 deconjugation by human and viral cross-reactive ubiquitin proteases. Biochemical Society transactions, Jul 2025. URL: https://doi.org/10.1042/bst20240859, doi:10.1042/bst20240859. This article has 1 citations and is from a peer-reviewed journal.

7. (wallace2023insightsintothe pages 10-11): Iona Wallace, Kheewoong Baek, J. Rajan Prabu, Ronnald Vollrath, Susanne von Gronau, Brenda A. Schulman, and Kirby N. Swatek. Insights into the isg15 transfer cascade by the ube1l activating enzyme. Nature Communications, Dec 2023. URL: https://doi.org/10.1038/s41467-023-43711-3, doi:10.1038/s41467-023-43711-3. This article has 29 citations and is from a highest quality peer-reviewed journal.

8. (wallace2023insightsintothe pages 6-7): Iona Wallace, Kheewoong Baek, J. Rajan Prabu, Ronnald Vollrath, Susanne von Gronau, Brenda A. Schulman, and Kirby N. Swatek. Insights into the isg15 transfer cascade by the ube1l activating enzyme. Nature Communications, Dec 2023. URL: https://doi.org/10.1038/s41467-023-43711-3, doi:10.1038/s41467-023-43711-3. This article has 29 citations and is from a highest quality peer-reviewed journal.

9. (clancy2023isgylationindependentprotectionof pages 1-2): Anne Clancy, Emma V. Rusilowicz-Jones, Iona Wallace, Kirby N. Swatek, Sylvie Urbé, and Michael J. Clague. Isgylation-independent protection of cell growth by usp18 following interferon stimulation. Biochemical Journal, 480:1571-1581, Jul 2023. URL: https://doi.org/10.1042/bcj20230301, doi:10.1042/bcj20230301. This article has 10 citations and is from a domain leading peer-reviewed journal.

10. (bonacci2025digdubsmechanismsand pages 3-3): Thomas Bonacci and Michael J. Emanuele. Dig-dubs: mechanisms and functions of isg15 deconjugation by human and viral cross-reactive ubiquitin proteases. Biochemical Society transactions, Jul 2025. URL: https://doi.org/10.1042/bst20240859, doi:10.1042/bst20240859. This article has 1 citations and is from a peer-reviewed journal.

11. (clancy2023isgylationindependentprotectionof pages 3-4): Anne Clancy, Emma V. Rusilowicz-Jones, Iona Wallace, Kirby N. Swatek, Sylvie Urbé, and Michael J. Clague. Isgylation-independent protection of cell growth by usp18 following interferon stimulation. Biochemical Journal, 480:1571-1581, Jul 2023. URL: https://doi.org/10.1042/bcj20230301, doi:10.1042/bcj20230301. This article has 10 citations and is from a domain leading peer-reviewed journal.

12. (zhu2024isgylationofthe pages 2-5): Junji Zhu, GuanQun Liu, Zuberwasim Sayyad, Christopher M. Goins, Shaun R. Stauffer, and Michaela U. Gack. Isgylation of the sars-cov-2 n protein by herc5 impedes n oligomerization and thereby viral rna synthesis. Journal of Virology, Sep 2024. URL: https://doi.org/10.1128/jvi.00869-24, doi:10.1128/jvi.00869-24. This article has 23 citations and is from a domain leading peer-reviewed journal.

13. (madaan2024isgylationenhancesdsrnainduced pages 5-6): Vidushi Madaan, Alexandra Kollara, David Spaner, and Theodore J. Brown. Isgylation enhances dsrna-induced interferon response and nfκb signaling in fallopian tube epithelial cells. Journal of Biological Chemistry, 300:107686, Sep 2024. URL: https://doi.org/10.1016/j.jbc.2024.107686, doi:10.1016/j.jbc.2024.107686. This article has 7 citations and is from a domain leading peer-reviewed journal.

14. (sarkar2023isg15itsroles pages 2-4): Lucky Sarkar, GuanQun Liu, and Michaela U. Gack. Isg15: its roles in sars-cov-2 and other viral infections. Trends in Microbiology, 31:1262-1275, Dec 2023. URL: https://doi.org/10.1016/j.tim.2023.07.006, doi:10.1016/j.tim.2023.07.006. This article has 55 citations and is from a domain leading peer-reviewed journal.

15. (madaan2024isgylationenhancesdsrnainduced pages 4-5): Vidushi Madaan, Alexandra Kollara, David Spaner, and Theodore J. Brown. Isgylation enhances dsrna-induced interferon response and nfκb signaling in fallopian tube epithelial cells. Journal of Biological Chemistry, 300:107686, Sep 2024. URL: https://doi.org/10.1016/j.jbc.2024.107686, doi:10.1016/j.jbc.2024.107686. This article has 7 citations and is from a domain leading peer-reviewed journal.

16. (zhu2024isgylationofthe pages 11-13): Junji Zhu, GuanQun Liu, Zuberwasim Sayyad, Christopher M. Goins, Shaun R. Stauffer, and Michaela U. Gack. Isgylation of the sars-cov-2 n protein by herc5 impedes n oligomerization and thereby viral rna synthesis. Journal of Virology, Sep 2024. URL: https://doi.org/10.1128/jvi.00869-24, doi:10.1128/jvi.00869-24. This article has 23 citations and is from a domain leading peer-reviewed journal.

17. (zhu2024isgylationofthe pages 5-7): Junji Zhu, GuanQun Liu, Zuberwasim Sayyad, Christopher M. Goins, Shaun R. Stauffer, and Michaela U. Gack. Isgylation of the sars-cov-2 n protein by herc5 impedes n oligomerization and thereby viral rna synthesis. Journal of Virology, Sep 2024. URL: https://doi.org/10.1128/jvi.00869-24, doi:10.1128/jvi.00869-24. This article has 23 citations and is from a domain leading peer-reviewed journal.

18. (chu2024herc5catalyzedisgylationpotentiates pages 1-4): Lei Chu, Yu Chen, Li Qian, Wei Meng, Juanjuan Zhu, Quanyi Wang, Chen Wang, and Shufang Cui. Herc5-catalyzed isgylation potentiates cgas-mediated innate immunity. bioRxiv, Jan 2024. URL: https://doi.org/10.1101/2023.01.03.522548, doi:10.1101/2023.01.03.522548. This article has 40 citations.

19. (yuan2023thefunctionalroles pages 2-5): Yin Yuan, Hai Qin, Huilong Li, Wanjin Shi, Lichen Bao, Shengtao Xu, Jun Yin, and Lufeng Zheng. The functional roles of isg15/isgylation in cancer. Molecules, 28:1337, Jan 2023. URL: https://doi.org/10.3390/molecules28031337, doi:10.3390/molecules28031337. This article has 46 citations.

20. (yuan2023thefunctionalroles pages 1-2): Yin Yuan, Hai Qin, Huilong Li, Wanjin Shi, Lichen Bao, Shengtao Xu, Jun Yin, and Lufeng Zheng. The functional roles of isg15/isgylation in cancer. Molecules, 28:1337, Jan 2023. URL: https://doi.org/10.3390/molecules28031337, doi:10.3390/molecules28031337. This article has 46 citations.

21. (OpenTargets Search: -UBA7): Open Targets Query (-UBA7, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

22. (wallace2023insightsintothe media bf4518e2): Iona Wallace, Kheewoong Baek, J. Rajan Prabu, Ronnald Vollrath, Susanne von Gronau, Brenda A. Schulman, and Kirby N. Swatek. Insights into the isg15 transfer cascade by the ube1l activating enzyme. Nature Communications, Dec 2023. URL: https://doi.org/10.1038/s41467-023-43711-3, doi:10.1038/s41467-023-43711-3. This article has 29 citations and is from a highest quality peer-reviewed journal.

23. (wallace2023insightsintothe media afc40555): Iona Wallace, Kheewoong Baek, J. Rajan Prabu, Ronnald Vollrath, Susanne von Gronau, Brenda A. Schulman, and Kirby N. Swatek. Insights into the isg15 transfer cascade by the ube1l activating enzyme. Nature Communications, Dec 2023. URL: https://doi.org/10.1038/s41467-023-43711-3, doi:10.1038/s41467-023-43711-3. This article has 29 citations and is from a highest quality peer-reviewed journal.

24. (sarkar2023isg15itsroles pages 12-14): Lucky Sarkar, GuanQun Liu, and Michaela U. Gack. Isg15: its roles in sars-cov-2 and other viral infections. Trends in Microbiology, 31:1262-1275, Dec 2023. URL: https://doi.org/10.1016/j.tim.2023.07.006, doi:10.1016/j.tim.2023.07.006. This article has 55 citations and is from a domain leading peer-reviewed journal.

Artifacts

• Edison artifact artifact-00
  

Citations

1. madaan2024isgylationenhancesdsrnainduced pages 1-2
2. wallace2023insightsintothe pages 6-7
3. bonacci2025digdubsmechanismsand pages 2-3
4. afsar2023cryoemstructuresof pages 1-2
5. alvarez2024unveilingthemultifaceted pages 2-4
6. clancy2023isgylationindependentprotectionof pages 1-2
7. wallace2023insightsintothe pages 1-2
8. zhu2024isgylationofthe pages 11-13
9. zhu2024isgylationofthe pages 5-7
10. madaan2024isgylationenhancesdsrnainduced pages 5-6
11. clancy2023isgylationindependentprotectionof pages 3-4
12. wallace2023insightsintothe pages 10-11
13. bonacci2025digdubsmechanismsand pages 3-3
14. zhu2024isgylationofthe pages 2-5
15. madaan2024isgylationenhancesdsrnainduced pages 4-5
16. yuan2023thefunctionalroles pages 2-5
17. yuan2023thefunctionalroles pages 1-2
18. https://doi.org/10.1038/s41467-023-43711-3
19. https://doi.org/10.1038/s41467-023-39780-z
20. https://doi.org/10.1016/j.jbc.2024.107686
21. https://doi.org/10.1128/jvi.00869-24
22. https://doi.org/10.1038/s41467-023-39780-z;
23. https://doi.org/10.1016/j.tim.2023.07.006;
24. https://doi.org/10.1038/s41467-023-43711-3;
25. https://doi.org/10.3390/vaccines12020153
26. https://doi.org/10.1042/bcj20230301;
27. https://doi.org/10.3390/molecules28031337
28. https://doi.org/10.1042/bst20240859
29. https://doi.org/10.1042/bcj20230301
30. https://doi.org/10.1101/2023.01.03.522548
31. https://doi.org/10.1038/s41467-023-39780-z,
32. https://doi.org/10.1038/s41467-023-43711-3,
33. https://doi.org/10.1016/j.jbc.2024.107686,
34. https://doi.org/10.1016/j.tim.2023.07.006,
35. https://doi.org/10.3390/vaccines12020153,
36. https://doi.org/10.1042/bst20240859,
37. https://doi.org/10.1042/bcj20230301,
38. https://doi.org/10.1128/jvi.00869-24,
39. https://doi.org/10.1101/2023.01.03.522548,
40. https://doi.org/10.3390/molecules28031337,

Deep Research Report: UBA7 (human)

Generated using OpenAI Deep Research API

UBA7 (Homo sapiens) – Comprehensive Gene Report

Gene Function and Molecular Mechanisms

UBA7 encodes ubiquitin-like modifier activating enzyme 7, an E1-class enzyme specialized for the ubiquitin-like protein ISG15 (www.proteinatlas.org). As the sole E1 in the ISG15 conjugation (ISGylation) pathway, UBA7 catalyzes the ATP-dependent activation of ISG15 and forms a high-energy thioester bond with the ISG15 C-terminus via its active-site cysteine (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). UBA7 then transfers ISG15 to its cognate E2 conjugating enzyme (UBE2L6, also known as UBCH8) to ultimately facilitate ISG15 attachment to target lysine residues on substrate proteins (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This mechanism is analogous to ubiquitination, involving a multi-step enzymatic cascade (E1–E2–E3), but UBA7 is highly specific for ISG15 (in contrast to the ubiquitin E1, UBA1) (pmc.ncbi.nlm.nih.gov). Structural studies confirm that while UBA7 shares a conserved domain architecture with other E1 enzymes (including an adenylation domain, a first and second catalytic cysteine half-domain, and a ubiquitin-fold domain) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), unique conformational arrangements underlie its strict specificity for ISG15 and its E2 partner (pmc.ncbi.nlm.nih.gov). Notably, UBA7-mediated ISG15 conjugation (termed ISGylation) can modify a broad range of interferon-stimulated proteins and other cellular proteins (e.g. p53) (www.proteinatlas.org). Through ISG15 attachment, UBA7 often alters the stability or activity of substrates – for example, ISGylation of the influenza A virus NS1 protein blocks its nuclear import, thereby inhibiting viral replication (www.proteinatlas.org). In summary, UBA7 functions as the initiating enzyme of the ISG15 system, activating ISG15 in an ATP-dependent manner and catalyzing its covalent linkage to target proteins, which is a critical post-translational modification in antiviral defense and other cellular pathways (www.proteinatlas.org) (pubmed.ncbi.nlm.nih.gov).

Cellular Localization and Subcellular Components

UBA7 protein is predominantly a cytosolic and nuclear enzyme, reflecting its role in modifying both cytoplasmic and nuclear substrates. Immunocytochemistry and proteomic analyses show that UBA7 is localized to the nucleoplasm and cytosol in human cells, with additional presence in vesicular structures (www.proteinatlas.org). Consistently, curated data list UBA7 in the nucleus (nucleoplasm) as well as the cytoplasm/cytosol compartments (www.proteinatlas.org). While sequence analysis predicted a single transmembrane region in UBA7 (suggesting a membrane association) (www.proteinatlas.org) (www.proteinatlas.org), experimental evidence does not indicate a stable membrane localization; instead UBA7 appears to be a soluble protein partitioned between cytosolic and nuclear compartments. The nuclear pool of UBA7 likely supports ISGylation of nuclear targets (such as transcription factors and PML nuclear body components), whereas cytosolic UBA7 can modify proteins in the cytoplasm or on vesicular organelles. Indeed, UBA7’s diffuse distribution aligns with the wide range of its substrates’ locations (e.g. cytosolic antiviral effectors and nuclear tumor suppressors). In summary, UBA7 is a predominantly intracellular enzyme found in the cytosol and nucleoplasm, enabling it to participate in post-translational modification processes throughout the cell (www.proteinatlas.org) (www.proteinatlas.org).

Biological Processes Involvement

UBA7 plays a pivotal role in several biological processes, chiefly centered on protein post-translational modification and innate immune defense. Its primary role is to mediate protein ISGylation (ISG15-protein conjugation), a process that parallels ubiquitination and is part of the broader ubiquitin-like protein conjugation pathway (www.proteinatlas.org) (www.proteinatlas.org). Through ISGylation, UBA7 is intimately involved in the antiviral immune response: together with ISG15, it restricts the replication of many viruses including influenza A, rabies, Sindbis, rotavirus, and human cytomegalovirus (www.proteinatlas.org). For example, UBA7-dependent ISGylation of influenza virus NS1 protein prevents NS1 from entering the nucleus, thereby curbing viral replication (www.proteinatlas.org). Similarly, ISG15 modification of HCMV protein UL26 (catalyzed by the UBA7 pathway) destabilizes UL26 and impedes its ability to block NF-κB signaling, contributing to antiviral immunity (www.proteinatlas.org). Beyond direct antiviral effects, UBA7 orchestrates interferon-driven immune signaling; notably, ISGylation of key signaling molecules (such as STAT1/STAT2 by the UBA7–ISG15 system) amplifies chemokine production and promotes the formation of antiviral PML nuclear bodies, thereby enhancing cytotoxic T cell recruitment and anti-tumor immunity (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov).

In addition to immunity, UBA7 is involved in protein homeostasis and degradation pathways. By tagging proteins with ISG15 or ubiquitin-like modifiers, UBA7 can target aberrant or regulatory proteins for turnover (a modification-dependent protein catabolic process) (www.proteinatlas.org). For instance, in the context of retinoic acid signaling in leukemia, UBA7 (as UBE1L) conjugates ISG15 to the PML-RARα oncoprotein, marking it for proteasomal degradation (pmc.ncbi.nlm.nih.gov). This promotes apoptosis of acute promyelocytic leukemia cells and is a crucial mechanism by which all-trans retinoic acid therapy reverses the oncogenic block in differentiation (www.pnas.org). Likewise, UBA7-mediated ISGylation of the cell-cycle regulator cyclin D1 leads to cyclin D1’s accelerated degradation, resulting in G1 arrest and growth suppression in lung epithelial cells (pubmed.ncbi.nlm.nih.gov). Through such actions, UBA7 influences cell cycle and apoptotic processes, especially in stressed or cancerous cells. There is also evidence linking UBA7 to the DNA damage response: ISG15 modification of p53 (a DNA damage-responsive tumor suppressor) suggests that UBA7 might modulate p53 stability or activity under genotoxic stress (www.proteinatlas.org). Overall, UBA7 is involved in innate immune processes (antiviral defense and interferon signaling), protein modification and catabolism, and regulation of cell proliferation and survival. These contributions are reflected in its Gene Ontology annotations, which include ISG15 conjugation (GO:0032020), protein ubiquitination (GO:0016567), protein modification by small protein transfer and related processes (www.proteinatlas.org).

Disease Associations and Phenotypes

Given its role in protein regulation and immunity, UBA7 has been implicated as a tumor suppressor and is associated with several diseases. In cancer biology, loss or reduced expression of UBA7 is frequently observed. The UBA7 gene resides on chromosome 3p21.3, a region that undergoes loss of heterozygosity (LOH) in many lung cancers: about 70–80% of non-small cell lung cancers and up to ~90–100% of small cell lung cancers show deletion of 3p21.3 (pmc.ncbi.nlm.nih.gov). Correspondingly, UBA7 expression is notably downregulated in lung cancer cell lines (pmc.ncbi.nlm.nih.gov). Functional studies indicate UBA7 exerts tumor-suppressive effects in lung epithelial cells by promoting ISGylation and degradation of oncogenic proteins – for example, UBA7-driven ISG15 conjugation of cyclin D1 leads to cyclin D1 repression, and ectopic UBA7 can also reduce EGFR levels in bronchial cells (pmc.ncbi.nlm.nih.gov). Consistent with a tumor suppressor role, re-introduction of UBA7 (UBE1L) in lung cancer models inhibits cell growth, and retinoid treatments (e.g. bexarotene) that upregulate UBA7 result in lowered cyclin D1 and proliferation indices in tumors (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov).

UBA7’s tumor-suppressive impact extends to other cancers as well. In breast cancer, UBA7 is significantly under-expressed in tumor tissues compared to normal, and low UBA7 levels correlate with more aggressive disease features and worse patient outcomes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Patients whose tumors have low UBA7 expression have poorer prognosis (shorter overall and relapse-free survival), whereas higher UBA7 levels are associated with improved survival (pmc.ncbi.nlm.nih.gov). A recent study identified UBA7 as an interferon-stimulated gene that acts as a tumor suppressor in breast cancer, facilitating an immune-friendly tumor microenvironment: UBA7-dependent ISGylation of STAT1/2 in tumor cells boosts chemokine secretion and T-cell infiltration, restraining tumor growth and metastasis (a finding mirrored by better survival in breast cancer patients with robust UBA7/ISG15 pathway activity) (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). UBA7 is thus being investigated as a prognostic biomarker and potential therapeutic target in breast carcinoma (pmc.ncbi.nlm.nih.gov).

In hematological malignancy, acute promyelocytic leukemia (APL) is a key example where UBA7 is involved in disease response. UBA7 (historically called UBE1L) is strongly induced by all-trans retinoic acid in APL cells and mediates ISG15 conjugation to the PML-RARα fusion protein (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This leads to degradation of PML-RARα and contributes to the differentiation and apoptosis of APL cells in therapy (www.pnas.org). Experimental overexpression of UBA7 in APL cell lines causes selective elimination of PML-RARα and cell death, confirming that UBA7 can phenocopy retinoid treatment by targeting the oncogene for destruction (www.pnas.org). These findings underscore UBA7’s role in the pathogenesis and treatment response of APL.

Beyond cancer, recent research suggests UBA7 may be relevant in certain myelodysplastic syndromes. In MDS patients with SF3B1 splicing-factor mutations, aberrant alternative splicing of UBA7 has been observed, leading to reduced UBA7 expression (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This spliceosome-mediated downregulation of UBA7 is associated with poorer prognosis in MDS and chronic lymphocytic leukemia, highlighting UBA7 as a potential disease modifier in these contexts (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Additionally, inherited or de novo loss-of-function mutations in UBA7 are rare (no Mendelian disease is currently attributed to UBA7), but functional knockout of Uba7 in mice produces notable phenotypes: Uba7-null mice fail to ISGylate proteins and show increased susceptibility to viral infections (pmc.ncbi.nlm.nih.gov). For example, Ube1L^(-/-) mice are significantly more vulnerable to influenza virus infection, underscoring the enzyme’s critical role in antiviral defense in vivo (pmc.ncbi.nlm.nih.gov). Overall, UBA7’s dysregulation is linked to oncogenesis (lung, breast cancers, leukemia), and its activity is vital for controlling viral disease, aligning with its function in immune surveillance and protein quality control.

Protein Domains and Structural Features

UBA7 is a 1012–amino acid protein (≈111 kDa) comprising several conserved domains characteristic of E1 enzymes (www.proteinatlas.org). The N-terminal portion contains a bipartite adenylation domain that binds ATP and the C-terminal glycine of ISG15, catalyzing the formation of ISG15–AMP (adenylate) (pmc.ncbi.nlm.nih.gov). This adenylation domain consists of an active adenylation subdomain (AAD) and an inactive adenylation subdomain (IAD), which together cradle ISG15 and ATP during the activation step (pmc.ncbi.nlm.nih.gov). UBA7 also harbors two distinct catalytic cysteine domains: the FCCH (First Catalytic Cysteine Half-domain) and the SCCH (Second Catalytic Cysteine Half-domain) (pmc.ncbi.nlm.nih.gov). The FCCH helps recognize and position the ISG15 adenylate, while the SCCH contains the critical active-site cysteine residue (Cys^m) that forms a thioester bond with the ISG15 C-terminus (pmc.ncbi.nlm.nih.gov). These domains undergo dramatic conformational changes during UBA7’s catalytic cycle; for instance, the SCCH domain rotates from an “open” to a “closed” conformation to bring the catalytic cysteine into alignment for thioester formation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Following ISG15 activation, UBA7’s C-terminal ubiquitin fold domain (UFD) engages the E2 enzyme (UBE2L6), facilitating E2 docking and thioester transfer of ISG15 from UBA7 to the E2’s active cysteine (pmc.ncbi.nlm.nih.gov). This modular domain organization – adenylation domain (for ATP binding and ISG15 adenylation), catalytic cysteine domains (for thioester generation), and UFD (for E2 recruitment) – is similar to that of the ubiquitin E1 (UBA1), reflecting their common evolutionary origin (pmc.ncbi.nlm.nih.gov).

Crystallographic and cryo-EM analyses have revealed that UBA7’s overall tertiary structure is highly ordered, with the ISG15 and E2 binding sites spatially coordinated. Notably, recent cryo-EM structures of the human UBA7–UBE2L6–ISG15 complex captured UBA7 in action, bound to ISG15 (in adenylate and thioester states) and the E2 enzyme (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These structures highlight subtle but important differences from the canonical ubiquitin E1: for example, in UBA7 the ISG15 molecule is oriented with a ~17° rotation relative to how ubiquitin binds UBA1, and UBA7’s FCCH domain is rotated ~25° compared to UBA1 (pmc.ncbi.nlm.nih.gov). Such differences explain UBA7’s “exquisite specificity” for ISG15 and UBE2L6 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The active-site region of UBA7 accommodates ISG15’s two-domain (tandem ubiquitin-like) structure, and specific residues in UBA7 contact ISG15’s C-terminal LRLRGG motif (shared with ubiquitin) to ensure correct positioning (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). UBA7 also contains sequence motifs for ATP binding (e.g. a conserved Adenosine-binding loop) and for magnesium coordination, typical of adenylate-forming enzymes. There is no signal peptide in UBA7 and it is not a secreted protein (www.proteinatlas.org). Some algorithms predict a single hydrophobic segment in UBA7 (hence “Predicted location: membrane”) (www.proteinatlas.org) (www.proteinatlas.org), but this likely represents an internal helix rather than a true transmembrane anchor, as experimental data show UBA7 is cytosolic/nuclear. In summary, UBA7’s structure comprises the necessary domains for a two-step enzyme: an adenylation domain (for ISG15 activation), a catalytic cysteine domain (for thioester formation), and a UFD domain (for E2 interaction), all arranged to carry out ISG15 transfer with high specificity (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Expression Patterns and Regulation

UBA7 is expressed ubiquitously in human tissues with generally low tissue specificity, although its expression levels can vary under certain physiological conditions. Baseline RNA and protein profiles show that UBA7 is present in most tissue types, with a slight enrichment in immune-related organs. For example, UBA7’s tissue expression cluster is associated with the spleen and immune response pathways (www.proteinatlas.org). It is also expressed in various cell types; single-cell RNA data indicate relatively higher UBA7 expression in granulocytes, intestinal enterocytes, and gastric mucus-secreting cells, among others (www.proteinatlas.org). In the blood, UBA7 is not detected as a secreted factor (consistent with it being an intracellular enzyme) (www.proteinatlas.org). The gene shows low regional specificity in the brain and is broadly expressed in both neural and non-neural cells (www.proteinatlas.org). At the protein level, immunohistochemistry confirms moderate to high nuclear staining in most tissues (www.proteinatlas.org), aligning with UBA7’s role as a ubiquitin-like modifier enzyme active in many cell types.

Regulation of UBA7 expression is tightly linked to immune signaling and differentiation cues. Type I interferons (IFN-α/β) robustly induce UBA7 transcription, as UBA7 is itself an interferon-stimulated gene (ISG) (pmc.ncbi.nlm.nih.gov). Upon IFN treatment or viral infection, UBA7 levels rise alongside ISG15 and other components of the ISGylation system, ensuring the cell is equipped to initiate ISG15 conjugation (pubmed.ncbi.nlm.nih.gov). This coordinated induction is part of the innate immune program; indeed, one study identified UBA7 as part of a network of ISGs whose upregulation leads to enhanced T cell–mediated tumor killing (pubmed.ncbi.nlm.nih.gov). UBA7 is also known to be a retinoic acid-inducible gene: exposure to all-trans retinoic acid or certain synthetic retinoids (e.g. bexarotene) can significantly increase UBA7 mRNA and protein expression in cells (www.pnas.org) (pubmed.ncbi.nlm.nih.gov). In APL cells, retinoid signaling through RAR/RXR receptors relieves transcriptional repression on the UBA7 gene (UBE1L), causing a rapid rise in UBA7 transcripts within hours of treatment (www.pnas.org). This induction is critical for the therapeutic degradation of PML-RARα in APL, as discussed above. Additionally, UBA7 expression can be modulated by certain chemicals; for example, polyphenols like curcumin were reported to upregulate UBA7 in bronchial epithelial cells, leading to downstream effects on EGFR levels (pmc.ncbi.nlm.nih.gov).

In cancer, downregulation of UBA7 is commonly observed, as noted. Large-scale analyses (e.g. TCGA data) show that tumors such as breast, lung, liver, and others often have lower UBA7 expression compared to normal tissue, and this low expression frequently correlates with worse clinical outcomes (pmc.ncbi.nlm.nih.gov). This suggests that in many cancers the UBA7 gene is suppressed (via chromosomal loss, epigenetic silencing, or splicing defects), potentially to evade its growth-suppressive ISGylation effects. On the other hand, leukemia cell lines (especially APL or others under inflammatory stimulation) can exhibit elevated UBA7 levels, fitting with the observation that UBA7 is cancer-enhanced in certain leukemia contexts (www.proteinatlas.org) where differentiation therapy or interferon pathways are active. Overall, UBA7 is broadly expressed and is dynamically regulated by immune signals (IFNs) and differentiation signals (retinoids). Its expression pattern mirrors its functional role – high during immune activation and in certain normal immune cells, but often lost or reduced in malignancies, underlining its importance in normal cellular defense and tumor suppression (pmc.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov).

Evolutionary Conservation

UBA7 and its substrate ISG15 represent a relatively recent innovation in vertebrate evolution. Both genes are found exclusively in vertebrates and are absent in invertebrate genomes (pubmed.ncbi.nlm.nih.gov). Phylogenetic analysis suggests that UBA7 arose by duplication of the ancestral ubiquitin-activating enzyme gene (UBA1) early in vertebrate evolution (pubmed.ncbi.nlm.nih.gov). Likewise, ISG15 appears to have originated from a duplication of a ubiquitin gene (UBB/UBC) around the same time (pubmed.ncbi.nlm.nih.gov). This paired emergence allowed the co-evolution of a dedicated ISG15 conjugation system. In fish (teleosts), Uba7 retains some of the ancestral promiscuity of UBA1 – notably, zebrafish Uba7 can activate ubiquitin as well as ISG15, and can function in the ubiquitin conjugation cascade in vitro and in vivo (pubmed.ncbi.nlm.nih.gov). This indicates that in early vertebrates, UBA7 was a less specialized E1 enzyme that could service multiple ubiquitin-like modifiers. However, during the evolution of tetrapods (amphibians, reptiles, birds, mammals), UBA7 became highly specialized for ISG15, losing significant ability to activate ubiquitin (pubmed.ncbi.nlm.nih.gov). This increased specificity likely provided a selective advantage by refining the interferon-induced ISG15 pathway independent of the ubiquitin system. The “ubiquitin-like” nature of ISG15 is reflected in its two-domain structure (tandem ubiquitin folds) and a C-terminal LRLRGG motif identical to ubiquitin’s; UBA7 evolved to recognize these features of ISG15 with high fidelity (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Across mammalian species, UBA7 is well conserved: human UBA7 shares high sequence identity with Uba7 in other mammals (e.g. rodents, ~80–90% identity at the amino acid level), and the key catalytic residues and domains are invariant, underscoring their essential function. Even in more distant vertebrates (birds, fish), UBA7 orthologs are recognizable and contain the same domain architecture and active-site motifs (pmc.ncbi.nlm.nih.gov). This conservation pattern – presence in all jawed vertebrates but absence from insects, worms, etc. – suggests that the ISG15/UBA7 system likely evolved alongside the interferon-based immune system unique to vertebrates. It serves as an example of how gene duplication followed by functional divergence created a new pathway: an ancestral ubiquitin E1 (UBA1) gave rise to UBA7 which diverged to specifically support a novel antiviral modification (ISGylation) (pubmed.ncbi.nlm.nih.gov). The evolutionary trajectory of UBA7 exemplifies how an “old” enzyme gained a “new” specific function through natural selection, with UBA7 becoming a dedicated ISG15 activator that augments vertebrate immune responses (pubmed.ncbi.nlm.nih.gov).

Relevant GO Terms

Molecular Function:
- ISG15 activating enzyme activity (GO:0019782): Catalysis of the activation of ISG15 (covalently linking ISG15 to E1 via thioester bond) (www.proteinatlas.org).
- Ubiquitin-like modifier activating enzyme activity (GO:0008641): General E1 activity for ubiquitin-like proteins, as performed by UBA7 in ISGylation (www.proteinatlas.org).
- ATP binding (GO:0005524): Ability to bind ATP, required for UBA7’s adenylation of ISG15 (www.proteinatlas.org).
- Protein binding (GO:0005515): Interacts with proteins such as E2 conjugating enzymes and substrates during the ISGylation process (www.proteinatlas.org).
(Additional relevant MF terms include “ligase activity” (GO:0016874) and “ubiquitin-protein transferase activity” (GO:0004842) indicating UBA7’s role in transferring ubiquitin-like modifiers (www.proteinatlas.org).)

Biological Process:
- ISG15-protein conjugation (GO:0032020): The process of covalently attaching ISG15 to target proteins (protein ISGylation), which UBA7 initiates (www.proteinatlas.org).
- Protein ubiquitination (GO:0016567): Involvement in ubiquitin-dependent protein modification; UBA7 is analogous to ubiquitin E1 and functionally links to protein degradation pathways (www.proteinatlas.org).
- Protein modification by small protein conjugation (GO:0032446): A broad category encompassing attachment of small proteins like ubiquitin/ISG15 to targets (www.proteinatlas.org).
- Modification-dependent protein catabolic process (GO:0019941): Protein degradation mediated by prior modification (such as ISG15 tagging of PML-RARα or cyclin D1 leading to proteasomal degradation) (www.proteinatlas.org).
- Cellular response to DNA damage stimulus (GO:0006974): Part of the DNA damage response network (likely via ISG15 modification of p53 and other factors) (www.proteinatlas.org).
(UBA7 also contributes to “defense response to virus” and interferon-mediated signaling, which are reflected in its role in antiviral ISGylation, although these may be annotated under related GO terms or UniProt keywords (www.proteinatlas.org) (pubmed.ncbi.nlm.nih.gov).)

Cellular Component:
- Nucleus (GO:0005634) & Nucleoplasm (GO:0005654): UBA7 is localized in the nucleus, particularly the nucleoplasm, where it can modify nuclear proteins (www.proteinatlas.org) (www.proteinatlas.org).
- Cytoplasm (GO:0005737) & Cytosol (GO:0005829): UBA7 is also found in the cytosolic compartment, modifying cytoplasmic proteins and participating in cytosolic antiviral complexes (www.proteinatlas.org) (www.proteinatlas.org).
- Vesicles (e.g. GO:0031982): Detected in association with vesicular structures inside cells (as per Human Protein Atlas), though not a membrane protein per se (www.proteinatlas.org).
(These localizations support UBA7’s function in both major intracellular compartments, consistent with its broad range of protein targets.)

Each of the above GO terms is supported by experimental evidence and curation: UBA7’s enzymatic activity, cellular distribution, and biological roles have been documented in the literature and captured in Gene Ontology annotations (www.proteinatlas.org) (www.proteinatlas.org), aiding functional annotation for this gene in the context of genome databases and the Gene Ontology project.